Literature DB >> 19837269

Novel SYT-SSX fusion transcript variants in synovial sarcoma.

Euthimios Dimitriadis1, Demetra Rontogianni, Anastasios Kyriazoglou, Anna Takou, Kostantina Frangia, Nikolaos Pandis, Theoni Trangas.   

Abstract

Synovial sarcoma (SS) is characterized by the t(X;18)(p11.2;q11.2) chromosomal translocation detected in >95% of cases. Through this translocation, one of the SYT genes, SYT4 on chromosome 18, is fused to one of the SSX genes on chromosome X. SYT4-SSX1 is the most common fusion subtype, present in approximately two thirds of the cases, followed by SYT4-SSX2 and, very rarely, SYT4-SSX4. Variant fusion transcripts occur less often, and most of the reported cases are the result of small insertions. Described here is a novel fusion variant containing a small deletion resulting in an alternative reading frame of the SSX part of the fusion gene. This fusion transcript may provide further insight into the oncogenic function of the SSX partner of the fusion gene.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19837269     DOI: 10.1016/j.cancergencyto.2009.06.012

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  8 in total

1.  Factors Associated With Survival in Patients With Synovial Cell Sarcoma of the Head and Neck: An Analysis of 167 Cases Using the SEER (Surveillance, Epidemiology, and End Results) Database.

Authors:  Jon Mallen-St Clair; Armin Arshi; Elliot Abemayor; Maie St John
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2016-06-01       Impact factor: 6.223

Review 2.  Adoptive cell therapy for sarcoma.

Authors:  Melinda Mata; Stephen Gottschalk
Journal:  Immunotherapy       Date:  2015       Impact factor: 4.196

3.  Recurrent and novel SS18-SSX fusion transcripts in synovial sarcoma: description of three new cases.

Authors:  Joanna Przybyl; Raf Sciot; Piotr Rutkowski; Janusz A Siedlecki; Vanessa Vanspauwen; Ignace Samson; Maria Debiec-Rychter
Journal:  Tumour Biol       Date:  2012-09-14

4.  Downstream and intermediate interactions of synovial sarcoma-associated fusion oncoproteins and their implication for targeted therapy.

Authors:  Joanna Przybyl; Monika Jurkowska; Piotr Rutkowski; Maria Debiec-Rychter; Janusz A Siedlecki
Journal:  Sarcoma       Date:  2012-03-25

5.  Release of circulating tumor cells and cell-free nucleic acids is an infrequent event in synovial sarcoma: liquid biopsy analysis of 15 patients diagnosed with synovial sarcoma.

Authors:  Dóra Mihály; Noémi Nagy; Gergő Papp; Zsuzsanna Pápai; Zoltán Sápi
Journal:  Diagn Pathol       Date:  2018-10-17       Impact factor: 2.644

6.  Primary pulmonary synovial sarcoma.

Authors:  Weixi Wang; Junhong Guo; Minwei Bao; Xiaogang Liu; Hao Wang; Cong Ye
Journal:  JTCVS Open       Date:  2022-02-24

7.  A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma.

Authors:  Robert G Maki; Achim A Jungbluth; Sacha Gnjatic; Gary K Schwartz; David R D'Adamo; Mary Louise Keohan; Michael J Wagner; Kelly Scheu; Rita Chiu; Erika Ritter; Jennifer Kachel; Israel Lowy; Lloyd J Old; Gerd Ritter
Journal:  Sarcoma       Date:  2013-02-27

8.  A Novel SS18-SSX Fusion-specific Antibody for the Diagnosis of Synovial Sarcoma.

Authors:  Esther Baranov; Matthew J McBride; Andrew M Bellizzi; Azra H Ligon; Christopher D M Fletcher; Cigall Kadoch; Jason L Hornick
Journal:  Am J Surg Pathol       Date:  2020-07       Impact factor: 6.298

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.